Stocklytics Platform
Asset logo for symbol PRME
Prime Medicine
PRME60
$5.79arrow_drop_up6.82%$0.37
High Growth
Asset logo for symbol PRME
PRME60

$5.79

arrow_drop_up6.82%

Performance History

Chart placeholder
Key Stats
Open$5.58
Prev. Close$5.57
EPS-2.18
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range5.25
5.60
52 Week Range4.11
15.74
Ratios
Revenue-
EBITDA Margin %-
EPS-2.18

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$878.28
Perf. (24h)
arrow_drop_up1.42%$12.32
Market Cap$790.81B
Price$554.70
Perf. (24h)
arrow_drop_down0.68%-$3.83
Market Cap$516.91B
Price$152.35
Perf. (24h)
arrow_drop_down1.22%-$1.89
Market Cap$371.20B
Price$124.38
Perf. (24h)
arrow_drop_down1.04%-$1.31
Market Cap$318.34B

About Prime Medicine (PRME)

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Keith Michael Gottesdiener M.D.
Headquarters
Cambridge
Employees
175
Exchange
NASDAQ
add Prime Medicine to watchlist

Keep an eye on Prime Medicine

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Prime Medicine's (PRME) price per share?

The current price per share for Prime Medicine (PRME) is $5.79. The stock has seen a price change of $0.37 recently, indicating a 6.83% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Prime Medicine (PRME)?

For Prime Medicine (PRME), the 52-week high is $15.75, which is 172% from the current price. The 52-week low is $4.11, the current price is 40.88% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Prime Medicine (PRME) a growth stock?

Prime Medicine (PRME) has shown an average price growth of 0.41% over the past three years. It has received a score of 87 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Prime Medicine as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Prime Medicine (PRME) stock price performance year to date (YTD)?

As of the latest data, Prime Medicine (PRME) has a year-to-date price change of -33.9%. Over the past month, the stock has experienced a price change of -7.21%. Over the last three months, the change has been 20.63%. Over the past six months, the figure is -12.41%. Looking at a longer horizon, the five-year price change stands at -72.16%.

help
Is Prime Medicine (PRME) a profitable company?

Prime Medicine (PRME) has a net income of -$198.13M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -8.18K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$191.29M. Furthermore, the EBITDA is -$194.68M.

help
What is the market capitalization of Prime Medicine (PRME)?

Prime Medicine (PRME) has a market capitalization of $650.57M. The average daily trading volume is 802.21K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level